| 1127 | Humans |
| 646 | Female |
| 529 | Male |
| 386 | Middle Aged |
| 337 | Adult |
| 301 | Aged |
| 204 | Animals |
| 159 | Risk Factors |
| 156 | Treatment Outcome |
| 144 | Adolescent |
| 138 | Young Adult |
| 131 | Genetic Predisposition to Disease |
| 124 | Polymorphism, Single Nucleotide |
| 107 | Child |
| 100 | Genome-Wide Association Study |
| 95 | Aged, 80 and over |
| 92 | Europe |
| 91 | Case-Control Studies |
| 88 | Mutation |
| 82 | Breast Neoplasms |
| 80 | Prospective Studies |
| 75 | Prognosis |
| 74 | Genotype |
| 73 | Time Factors |
| 69 | Child, Preschool |
| 68 | Cohort Studies |
| 67 | Follow-Up Studies |
| 59 | Infant |
| 56 | Phenotype |
| 51 | Double-Blind Method |
| 50 | Risk Assessment |
| 49 | Practice Guidelines as Topic |
| 49 | Age Factors |
| 48 | Genetic Variation |
| 47 | Retrospective Studies |
| 46 | European Continental Ancestry Group |
| 44 | Consensus |
| 42 | Incidence |
| 42 | Global Health |
| 42 | Australia |
| 41 | Risk |
| 41 | Biomarkers |
| 40 | Phylogeny |
| 40 | Mice |
| 40 | Antineoplastic Combined Chemotherapy Protocols |
| 39 | Randomized Controlled Trials as Topic |
| 39 | Disease Progression |
| 38 | Severity of Illness Index |
| 38 | Reproducibility of Results |
| 38 | Proportional Hazards Models |
| 37 | Neoplasm Staging |
| 37 | Disease-Free Survival |
| 36 | Ovarian Neoplasms |
| 36 | Alleles |
| 35 | Survival Rate |
| 35 | Neoplasms |
| 35 | Antineoplastic Agents |
| 34 | Societies, Medical |
| 34 | International Cooperation |
| 34 | Brain |
| 33 | United States |
| 33 | Pregnancy |
| 33 | Infant, Newborn |
| 32 | Registries |
| 32 | Kaplan-Meier Estimate |
| 32 | Genetic Loci |
| 32 | Genetic Association Studies |
| 31 | Signal Transduction |
| 31 | Biodiversity |
| 30 | Surveys and Questionnaires |
| 30 | Odds Ratio |
| 30 | Magnetic Resonance Imaging |
| 29 | Terminology as Topic |
| 29 | Sequence Analysis, DNA |
| 29 | Prevalence |
| 29 | Ecosystem |
| 28 | Drug Therapy, Combination |
| 27 | Genome, Human |
| 26 | Genomics |
| 26 | Evolution, Molecular |
| 26 | Clinical Trials as Topic |
| 25 | Research Design |
| 25 | Quantitative Trait Loci |
| 25 | Quality of Life |
| 24 | Survival Analysis |
| 24 | Drug Administration Schedule |
| 24 | Cardiovascular Diseases |
| 23 | Computational Biology |
| 23 | Chromosome Mapping |
| 22 | Predictive Value of Tests |
| 22 | Multivariate Analysis |
| 22 | Molecular Sequence Data |
| 22 | Evidence-Based Medicine |
| 22 | Body Mass Index |
| 21 | Internationality |
| 21 | High-Throughput Nucleotide Sequencing |
| 21 | Hematopoietic Stem Cell Transplantation |
| 21 | Exome |
| 21 | Disease Management |
| 21 | Cross-Sectional Studies |
| 21 | Conservation of Natural Resources |
| 21 | Algorithms |
| 20 | United Kingdom |
| 20 | Stroke |
| 20 | Prostatic Neoplasms |
| 20 | Haplotypes |
| 20 | Gene Expression Profiling |
| 19 | Recurrence |
| 19 | Pedigree |
| 19 | Melanoma |
| 19 | HIV Infections |
| 19 | Gene Expression Regulation |
| 19 | DNA Mutational Analysis |
| 18 | Models, Theoretical |
| 18 | Logistic Models |
| 18 | Heart Failure |
| 18 | Base Sequence |
| 18 | Amino Acid Sequence |
| 17 | Protein Kinase Inhibitors |
| 17 | Models, Biological |
| 17 | Guidelines as Topic |
| 17 | Diabetes Mellitus, Type 2 |
| 17 | Colorectal Neoplasms |
| 16 | Skin Neoplasms |
| 16 | Sex Factors |
| 16 | Outcome Assessment (Health Care) |
| 16 | Neoplasm Recurrence, Local |
| 16 | Neoplasm Metastasis |
| 16 | Myocardial Infarction |
| 16 | Meta-Analysis as Topic |
| 16 | Lung Neoplasms |
| 16 | Longitudinal Studies |
| 16 | Hospitalization |
| 16 | Genetics, Population |
| 16 | Cell Line, Tumor |
| 16 | Blood Pressure |
| 16 | Biomarkers, Tumor |
| 16 | Biological Evolution |
| 16 | Bayes Theorem |
| 16 | Aging |
| 15 | Heterozygote |
| 15 | Genetic Testing |
| 15 | Gene Frequency |
| 15 | Exercise |
| 15 | Databases, Factual |
| 15 | Cause of Death |
| 15 | Asthma |
| 14 | Smoking |
| 14 | Sensitivity and Specificity |
| 14 | Recombinant Proteins |
| 14 | Intellectual Disability |
| 14 | France |
| 14 | Dose-Response Relationship, Drug |
| 14 | Disease Models, Animal |
| 14 | Climate Change |
| 14 | BRCA1 Protein |
| 14 | Arthritis, Rheumatoid |
| 14 | Antiviral Agents |
| 14 | Age Distribution |
| 13 | Species Specificity |
| 13 | Software |
| 13 | Sex Distribution |
| 13 | Neoplasms, Glandular and Epithelial |
| 13 | Neoplasm Grading |
| 13 | Models, Statistical |
| 13 | Germ-Line Mutation |
| 13 | Gene Expression Regulation, Neoplastic |
| 13 | Diet |
| 13 | Comorbidity |
| 13 | Cognition |
| 13 | Carbon Dioxide |
| 13 | Antibodies, Monoclonal |
| 13 | Antibodies, Monoclonal, Humanized |
| 13 | Anti-Bacterial Agents |
| 13 | Age of Onset |
| 12 | Vaccination |
| 12 | Obesity |
| 12 | Mutation, Missense |
| 12 | Models, Molecular |
| 12 | Hypoglycemic Agents |
| 12 | Epigenesis, Genetic |
| 12 | Databases, Genetic |
| 12 | Combined Modality Therapy |
| 12 | Cell Line |
| 12 | Blood Glucose |
| 12 | Biomedical Research |
| 12 | Asian Continental Ancestry Group |
| 12 | Alzheimer Disease |
| 11 | Tumor Suppressor Proteins |
| 11 | Trees |
| 11 | Transcription Factors |
| 11 | ROC Curve |
| 11 | RNA, Messenger |
| 11 | Pyrimidines |
| 11 | Proteins |
| 11 | Prosthesis Design |
| 11 | Population Dynamics |
| 11 | Nuclear Proteins |
| 11 | New Zealand |
| 11 | Neuropsychological Tests |
| 11 | Mortality |
| 11 | Models, Genetic |
| 11 | International Agencies |
| 11 | Hepatitis C, Chronic |
| 11 | HEK293 Cells |
| 11 | Geography |
| 11 | Endometrial Neoplasms |
| 11 | Electrocardiography |
| 11 | Datasets as Topic |
| 11 | DNA Copy Number Variations |
| 11 | Cooperative Behavior |
| 11 | Computer Simulation |
| 11 | Cognition Disorders |
| 11 | Climate |
| 11 | Cholesterol, LDL |
| 11 | Cells, Cultured |
| 11 | Carbon |
| 10 | Tuberculosis |
| 10 | Transplantation Conditioning |
| 10 | Renal Insufficiency, Chronic |
| 10 | Remission Induction |
| 10 | Regression Analysis |
| 10 | Receptor, ErbB-2 |
| 10 | Postoperative Complications |
| 10 | Plasmodium falciparum |
| 10 | Mice, Inbred C57BL |
| 10 | Membrane Proteins |
| 10 | Malaria |
| 10 | Immunosuppressive Agents |
| 10 | Imidazoles |
| 10 | Hemorrhage |
| 10 | Gene Expression |
| 10 | DNA, Mitochondrial |
| 10 | Cost-Benefit Analysis |
| 10 | Coronary Artery Disease |
| 9 | Viral Load |
| 9 | Tropical Climate |
| 9 | Temperature |
| 9 | Selection, Genetic |
| 9 | Ribavirin |
| 9 | Reproduction |
| 9 | Receptors, Estrogen |
| 9 | Rats |
| 9 | Promoter Regions, Genetic |
| 9 | Polyethylene Glycols |
| 9 | Papillomavirus Infections |
| 9 | Molecular Sequence Annotation |
| 9 | Menopause |
| 9 | Mendelian Randomization Analysis |
| 9 | Liver Cirrhosis, Biliary |
| 9 | Information Dissemination |
| 9 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 9 | Hospital Mortality |
| 9 | Genome, Bacterial |
| 9 | Genes, BRCA2 |
| 9 | Extinction, Biological |
| 9 | Environment |
| 9 | Drug Combinations |
| 9 | Diabetes Mellitus |
| 9 | DNA |
| 9 | DNA-Binding Proteins |
| 9 | Critical Illness |
| 9 | Cost of Illness |
| 9 | Chemotherapy, Adjuvant |
| 9 | Cattle |
| 9 | Carrier Proteins |
| 9 | Asia |
| 9 | Antifungal Agents |
| 9 | Anticholesteremic Agents |
| 9 | Acute Disease |
| 9 | Acute Coronary Syndrome |
| 8 | World Health Organization |
| 8 | Water |
| 8 | Sulfonamides |
| 8 | Soil |
| 8 | Seasons |
| 8 | Schizophrenia |
| 8 | Rheumatology |
| 8 | Reference Standards |
| 8 | Rare Diseases |
| 8 | Precision Medicine |
| 8 | Postmenopause |
| 8 | Platelet Aggregation Inhibitors |
| 8 | Pilot Projects |
| 8 | Phylogeography |
| 8 | Percutaneous Coronary Intervention |
| 8 | Pancreatic Neoplasms |
| 8 | Observational Studies as Topic |
| 8 | Nerve Tissue Proteins |
| 8 | Molecular Targeted Therapy |
| 8 | Liver Neoplasms |
| 8 | Liver Cirrhosis |
| 8 | Interferon-alpha |
| 8 | Intensive Care Units |
| 8 | Insulin |
| 8 | In Situ Hybridization, Fluorescence |
| 8 | Hypertension |
| 8 | History, Ancient |
| 8 | Hippocampus |
| 8 | Hepacivirus |
| 8 | Health Services Accessibility |
| 8 | Genome |
| 8 | Genome, Plant |
| 8 | Genes, BRCA1 |
| 8 | Gene Dosage |
| 8 | Forced Expiratory Volume |
| 8 | Exons |
| 8 | Enzyme-Linked Immunosorbent Assay |
| 8 | Enhancer Elements, Genetic |
| 8 | Echocardiography |
| 8 | Early Detection of Cancer |
| 8 | Diagnosis, Differential |
| 8 | Developing Countries |
| 8 | Dementia |
| 8 | DNA Methylation |
| 8 | Cholangitis |
| 8 | Cerebral Hemorrhage |
| 8 | Cell Proliferation |
| 8 | Carcinoma |
| 8 | Canada |
| 8 | Bipolar Disorder |
| 8 | BRCA2 Protein |
| 8 | Atmosphere |
| 8 | Antihypertensive Agents |
| 8 | Administration, Oral |
| 8 | Adaptation, Physiological |
| 7 | Zebrafish |
| 7 | Transplantation, Homologous |
| 7 | Transcriptome |
| 7 | Stents |
| 7 | Statistics as Topic |
| 7 | Socioeconomic Factors |
| 7 | Sequence Alignment |
| 7 | Secondary Prevention |
| 7 | Seawater |
| 7 | Quinazolines |
| 7 | Quality Control |
| 7 | Pyridones |
| 7 | Pyridines |
| 7 | Pulmonary Disease, Chronic Obstructive |
| 7 | Protozoan Proteins |
| 7 | Proto-Oncogene Proteins B-raf |
| 7 | Protein Binding |
| 7 | Population Surveillance |
| 7 | Polymerase Chain Reaction |
| 7 | Patient Selection |
| 7 | Organ Size |
| 7 | Observer Variation |
| 7 | Netherlands |
| 7 | Neoplasm Invasiveness |
| 7 | Medical Oncology |
| 7 | Mass Screening |
| 7 | MCF-7 Cells |
| 7 | Kidney Neoplasms |
| 7 | Internet |
| 7 | Immunohistochemistry |
| 7 | Image Processing, Computer-Assisted |
| 7 | Hyperlipoproteinemia Type II |
| 7 | Huntington Disease |
| 7 | Homeodomain Proteins |
| 7 | Heart Valve Prosthesis |
| 7 | Germany |
| 7 | Genotyping Techniques |
| 7 | Genetic Markers |
| 7 | Fossils |
| 7 | Forests |
| 7 | Exercise Test |
| 7 | Epilepsy |
| 7 | Environmental Monitoring |
| 7 | Delphi Technique |
| 7 | Chronic Disease |
| 7 | Cardiology |
| 7 | Carcinoma, Renal Cell |
| 7 | Brain Neoplasms |
| 7 | Bone Density Conservation Agents |
| 7 | Autoimmune Diseases |
| 7 | Atrial Fibrillation |
| 7 | Area Under Curve |
| 7 | Apoptosis |
| 7 | Allergens |
| 7 | Adiposity |
| 7 | Adaptor Proteins, Signal Transducing |
| 6 | Vitamin D |
| 6 | Uterine Cervical Neoplasms |
| 6 | Triglycerides |
| 6 | Travel |
| 6 | Transcription, Genetic |
| 6 | Tomography, X-Ray Computed |
| 6 | Taste |
| 6 | Spain |
| 6 | Salvage Therapy |
| 6 | Research |
| 6 | Recombinant Fusion Proteins |
| 6 | Quality-Adjusted Life Years |
| 6 | Pyrazoles |
| 6 | Protein Conformation |
| 6 | Pregnancy Complications |
| 6 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| 6 | Plants |
| 6 | Peritoneal Neoplasms |
| 6 | Perindopril |
| 6 | Papillomavirus Vaccines |
| 6 | Palliative Care |
| 6 | Oligopeptides |
| 6 | Occupational Exposure |
| 6 | North America |
| 6 | Muscles |
| 6 | Muscle, Skeletal |
| 6 | Multiple Sclerosis |
| 6 | Mitochondria |
| 6 | Lupus Erythematosus, Systemic |
| 6 | Lung |
| 6 | Linkage Disequilibrium |
| 6 | Leukemia, Lymphocytic, Chronic, B-Cell |
| 6 | Injections, Subcutaneous |
| 6 | Inflammation |
| 6 | Indoles |
| 6 | Image Interpretation, Computer-Assisted |
| 6 | Hypertension, Pulmonary |
| 6 | Hemoglobin A, Glycosylated |
| 6 | HLA Antigens |
| 6 | Grassland |
| 6 | Glomerular Filtration Rate |
| 6 | Glioma |
| 6 | Gene Regulatory Networks |
| 6 | Fluorouracil |
| 6 | Fishes |
| 6 | Fatigue |
| 6 | Estrogen Receptor alpha |
| 6 | Equipment Design |
| 6 | Environmental Exposure |
| 6 | Educational Status |
| 6 | Drug-Eluting Stents |
| 6 | Drug Resistance, Neoplasm |
| 6 | Diabetes Mellitus, Type 1 |
| 6 | Developed Countries |
| 6 | Dermatitis, Atopic |
| 6 | Databases, Protein |
| 6 | DNA Transposable Elements |
| 6 | Coronary Thrombosis |
| 6 | Continental Population Groups |
| 6 | Cognitive Dysfunction |
| 6 | Cluster Analysis |
| 6 | Clinical Trials, Phase III as Topic |
| 6 | Clinical Decision-Making |
| 6 | Cholesterol, HDL |
| 6 | Carcinoma, Hepatocellular |
| 6 | Carbon Cycle |
| 6 | Camptothecin |
| 6 | Brain Ischemia |
| 6 | Bone Neoplasms |
| 6 | Biomass |
| 6 | Binding Sites |
| 6 | Bacterial Proteins |
| 6 | Athletic Injuries |
| 6 | Athletes |
| 6 | Arrhythmias, Cardiac |
| 6 | Aortic Valve |
| 6 | Antirheumatic Agents |
| 6 | Antineoplastic Agents, Hormonal |
| 6 | Antimalarials |
| 6 | Anti-HIV Agents |
| 6 | Alternative Splicing |
| 6 | Alcohol Drinking |
| 6 | Agriculture |
| 6 | Adenocarcinoma |
| 5 | Wings, Animal |
| 5 | Vital Capacity |
| 5 | Up-Regulation |
| 5 | Ubiquitin-Protein Ligases |
| 5 | Tumor Suppressor Protein p53 |
| 5 | Triazoles |
| 5 | Trastuzumab |
| 5 | Tomography, Optical Coherence |
| 5 | Thyroid Neoplasms |
| 5 | Telomere Homeostasis |
| 5 | T-Lymphocytes |
| 5 | Syndrome |
| 5 | Sports |
| 5 | Sports Medicine |
| 5 | Sjogren's Syndrome |
| 5 | Sirolimus |
| 5 | Sex Characteristics |
| 5 | Sequence Homology, Amino Acid |
| 5 | Rituximab |
| 5 | Rhinitis, Allergic |
| 5 | Rheumatic Diseases |
| 5 | Respiration, Artificial |
| 5 | Repressor Proteins |
| 5 | Renal Dialysis |
| 5 | Reference Values |
| 5 | Real-Time Polymerase Chain Reaction |
| 5 | RNA, Viral |
| 5 | Quinolines |
| 5 | Quality of Health Care |
| 5 | Pyrimidinones |
| 5 | Pulmonary Medicine |
| 5 | Public Health |
| 5 | Proteomics |
| 5 | Protein Isoforms |
